Introduction {#S0001}
============

Breast cancer is the most common type of cancer in women worldwide, and the second most common cause of cancer death in women in developed countries.[@CIT0001],[@CIT0002] For its early diagnosis breast cancer screening programs are available in many countries across the world. In many countries this involves the use of 2D digital mammography (DM), an X-ray 2D imaging technique.[@CIT0003] Women within a certain age range (often 40--70 years, depending on country) are called to attend breast cancer screening, over regular periods in their lifetime (normally every 1--3 years, depending on country), with the aim to diagnose the disease at an earlier than the symptoms appearance stage and reduce the risk of death from breast cancer. Breast cancer screening mortality from breast cancer can been reduced by 25--31% among invited women and 38--48% among those who actually attended screening.[@CIT0004]

Technology {#S0001-S2001}
----------

In DM, images of the breast are acquired in two views, the craniocaudal (CC) and the mediolateral oblique (MLO), for assessment, even though three-view DM has also been considered.[@CIT0005] Assuming "head to toes" of a standing patient undergoing breast imaging on a DM system is the z-axis, and the detector surface is below the patient breast and perpendicular to the z-axis, CC is a view in the direction "head to toes" and parallel to the z-axis, while MLO is a view at an angle less than ±90° to the z-axis.

Digital breast tomosynthesis (DBT) is a more advanced breast cancer imaging technique, with an acquisition geometry very similar to that used in DM. It involves the acquisition of low-dose 2D X-ray projection images of the breast over a limited angular range. For the projections acquisition, the X-ray tube rotates around the static and compressed breast ([Figure 1](#F0001){ref-type="fig"}). A reconstruction algorithm is then used to process the projections and reconstruct a quasi-3D image and image planes, parallel to the detector. This algorithm uses the different locations in the projections of the same tissue to compute their vertical position, thereby estimating the 3D distribution of the tissue. DBT images can be acquired in both CC and MLO views, as in DM ([Figure 1](#F0001){ref-type="fig"}). The dose of a single view DBT is 2.19 mGy for 50--60 mm thick breasts, which is slightly higher than the corresponding one-view DM of 1.88 mGy.[@CIT0006] Figure 1Breast digital tomosynthesis projection acquisition (CC-view): the X-ray source rotates around the static and compressed breast over a limited angular range, while the detector is static or rotates slightly.

Some of the DM and DBT manufacturers provide an additional imaging modality together with DBT called synthetic mammography (SM). SM involves the synthesis of a DM image of the breast using the 2D projection images acquired using DBT, at no cost of any additional dose. A mathematical algorithm is applied to the acquired DBT projections by summing and filtering the stack of reconstructed sections. A region of interest in the synthesized image can then be contrast-enhanced using mathematical filters.

Current status {#S0001-S2002}
--------------

Digital Breast Tomosynthesis (DBT), with or without Digital Mammography (DM) and/or Synthetic Mammography (SM), has been introduced in breast cancer screening by national breast screening programs in some countries,[@CIT0007] it is under consideration for its introduction in others,[@CIT0008],[@CIT0009] while independent practices might create their own implementation protocols. There is currently no standardisation on if and how to implement DBT in screening, and in many cases there is lack of official guidance on the optimum usage of each commercially available system.

Several national breast screening programs and independent breast screening centres are independently investigating the implementations with which DBT could be introduced in breast cancer screening. DBT has been considered being used in screening alone, thus fully replacing DM. DBT has also been considered being used in combination with DM or in combination with SM, with SM replacing DM. Investigations to introduce one view of DBT only, with or without DM, have also been carried out.

Clinical observer studies are widely used for the assessment of the different implementations with which DBT can be introduced in screening. The process of clinical observer studies involves the acquisition and use of either prospective or retrospective realistic breast cancer images under specific implementations, and their observation by real observers (normally radiologists) under clinically relevant conditions. The outcome of these studies is the evaluation of metrics that assess the performance of systems. Often the following metrics are assessed: sensitivity (true positive rate), specificity (true negative rate), recall rate and cancer detection rate (the number of cancers detected per 1000 screening mammograms) of the different implementations and their direct comparison. In addition, the receiver operating characteristics (ROC or JAFROC) analysis is commonly undertaken for the evaluation of the area under curve (AUC) of the ROC curve (sensitivity versus 1-specificty), which represents how well a DBT implementation can distinguish between two diagnostic groups.[@CIT0010] In JAFROC analysis, AUC represents a figure of merit defined as the probability that a correctly marked lesion is rated higher than the highest-rated mark on a normal or benign case.[@CIT0011]

This work {#S0001-S2003}
---------

A lot of review work has been completed on the use of DBT in breast cancer screening.[@CIT0008],[@CIT0012],[@CIT0013] However, to the best of our knowledge, no review work has summarised clinical observer studies separately for each of the four common methods with which DBT can be implemented in screening: (2-view) DBT alone \[DBT or 2vDBT\],(2-view) DBT with (2-view) DM \[DM&DBT\],Single-view DBT \[1vDBT\] with or without single or double view DM \[1vDM or 2vDM\],(2-view) DBT with (2-view) SM \[DBT&SM\].

Furthermore, DBT systems by different manufacturers vary to a big extent in terms of technical specifications. DBT variations between manufactures include the geometry of the system, including the number of projection images and the angular range over which they are obtained, the height of the center of rotation of the tube in relation to the detector surface, whether the projection images are obtained while the tube is in motion, or with a step and-shoot process. Other variations between different DBT systems might include whether an antiscatter grid is used, the reconstruction algorithm, the pixel size of the reconstructed images and the dose levels. The system design details normally involve a trade-off. For example, a wider angular range is expected to enhance in-depth resolution, which might aid radiological interpretation, but this comes at the cost of lower in-plane resolution. Therefore, when assessing DBT implementations it is important to assess each manufacturer separately.

The aim of this review is to carry out a manufacturer- and metric- specific summary of studies on four common DBT implementations. The aim is not to support any of the DBT implementation methods, but only to distinguish them and provide a summary of studies for each of them. This could make healthcare providers more aware of the advantages and limitations of each implementation method of each DBT system.

Materials and methods {#S0002}
=====================

An exhaustive literature search was undertaken using the pubmed search engine and the quotation "tomosynthesis breast cancer screening". Six hundred and seventy seven (677) studies published from November 1997 to December 2018 were identified. As a minimum the abstracts of all studies were reviewed to consider whether the study meets the inclusion criteria. For studies to meet the inclusion criteria they needed to include: the comparison of at least one of the four implementations discussed in section "Introduction": (1) DBT, (2) DM&DBT, (3) 1vDBT with or without 1vDM or 2vDM and (4) DBT&SM, directly with DM alone and/or with each other, andthe assessment of at least one of the five metrics: (a) sensitivity, (b) specificity, (c) AUC of the ROC or JAFROC analysis, (d) recall rate and (e) cancer detection rate. Figure 2The strategy and scope of this review, the number of identified articles and the number considered eligible for inclusion in this work. The decision taken at each step of the eligibility process is shown in a red box.

Out of the 677 studies identified through the pubmed search engine, non-English studies and studies that included the evaluation of other breast imaging modalities, other than DM and DBT, were excluded. The rest of the articles were then divided into different types of articles based on their type (original studies, reviews and documents, guidelines and position papers, case studies, financial studies, surveys and others). The original studies were read in most detail and were separated into groups based on the methodologies that were used (clinical, development and technical, simulation and theoretical, characterization and features). Development and technical studies included those that studied the development and/or evaluation of prototypes, reconstruction algorithms, computer-aided diagnosis, measurement of radiation dose, time, effect of density in imaging and biopsy techniques. The studies that used clinical data (real patient images, defined as clinical studies) were further studied. Of those, 141 were included in this review. Common metrics that were assessed in original clinical studies, which were excluded from the review ([Figure 2](#F0002){ref-type="fig"}, non-eligible papers), included the size of lesions, type of lesions, BIRADS score, mass visibility, time of interpretation and breast density. Clinical studies on surveillance imaging and the role of access to prior mammograms, as well as studies that did not include enough details on their methodology were also excluded. A summary of the strategy and scope, the number of identified articles and the number considered eligible for inclusion in this review are shown in [Figure 2](#F0002){ref-type="fig"}.

Results: studies on the optimal use of digital breast tomosynthesis in screening {#S0003}
================================================================================

This section presents the evidence (necessary details of each original study including methods, results and conclusions) in subjections \"Sensitivity\", \"Specificity\", \"AUC\", \"Recall rate\", \"Cancer detection rate\" that may lead, where possible, to conclusions for the optimal use of each DBT implementation (subjections Summary). To act as a quick reference tool for readers, the results are systematically described (in the four sections below; "Digital breast tomosynthesis alone versus digital mammography", "Digital breast tomosynthesis with digital mammography versus digital mammography", "Single view digital breast tomosynthesis versus digital mammography" and "Digital breast tomosynthesis with synthetic mammography versus digital mammography") for each of the four common implementations with which DBT could be used in screening: (1) DBT, (2) DM&DBT, (3) 1vDBT with or without 1vDM or 2vDM and (4) DBT&SM. Each implementation method is compared to the current practice gold standard, 2-view DM alone, and/or with each other. For each implementation method, the literature corresponding to the five metrics in question (sensitivity, specificity, AUC, recall rate, cancer detection rate) are separately discussed. The results section is therefore split into 20 different subsections in total.

In this section we report the findings of the authors; namely if the authors consider a result to be "statistically significant" then we report it here as "significant". However, each study might use a different criterion for statistical significance, so readers are encouraged to read the individual papers for further details. Direct comparison of different technologies even by the same manufacturer is difficult, therefore in this work, the version of the system used in each original study is specified, where appropriate.

Digital breast tomosynthesis alone versus digital mammography {#S0003-S2001}
-------------------------------------------------------------

Many imaging centres may consider replacing DM with the new and more advanced DBT systems, due to its 3D capabilities. However, for DBT alone to fully replace DM in breast cancer screening it would have to provide at least the same diagnostic capabilities with DM, at similar dose levels. Normally, the mean glandular dose levels by 1vDBT are considered 1--1.5 times that of 1vDM.[@CIT0006],[@CIT0014] This section presents clinical observer studies that investigated whether DBT by different manufacturers have shown any outperformance in comparison to DM, in terms of sensitivity, specificity, AUC, recall rate and cancer detection rate. [Tables 1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"} summarize the studies that were identified for the purposes of this review for the comparison of DBT alone to DM alone.Table 1Sensitivity, specificity and AUC - comparison of DBT alone to DMAuthorYearVendorNSensitivitySpecificityAUCAsbeutal et al2018GE58DM: 73.5%, DBT: 100% \[Y\]DM: 67.7%, DBT: 94% \[Y\]DM: 0.706, DBT: 0.984 \[Y\]Bian et al^c^2016Hologic631DM 58.8%, DBT: 68.1% \[Y\]DM: 86.7%%, DBT: 95.2% \[Y\]--Brandt et al^b^2013Hologic146DM: 100%, DBT: 88----100%DM: 94%, DBT: 89----94%--Clauser et al^a^2016DM: Siemens, GE, Sectra DBT: Siemens150DM: 88----90%, DBT: 78----98%--DM: 0.829, DBT: 0.833Dibble et al^d^2018Hologic118DM: 32%, DBT: 59% \[Y\]DM: 93%, DBT: 93% \[N\]DM: \<0.75, DBT:\>0.75Good et al2008Hologic30----DM: 0.60, DBT: 0.62 \[N\]Li et al^a^2018Hologic305DM: 88.8%, DBT: 92.9% \[N\]DM 75.2%:, DBT: 87.9% \[Y\]--Seo et al2016Hologic203DM: 73.2%, DBT:78.3% \[Y\]DM: 61%, DBT: 63% \[N\]DM: 0.775, DBT: 0.807 \[Y\]Spangler et al^a^2011Hologic100DM: 84%, DBT: 75%DM: 71%, DBT: 64%DM: 0.76, DBT: 0.72 \[N\]Tagliafico et al^a^2015Hologic107DM: 100%, DBT: 91.1%DM: 94.6%, DBT: 100%--Terrstra et al2010Hologic513DM: 92.9%, DBT: 92.9% \[N\]DM: 86.1%, DBT: 84.4%--Wallis et al2012Sectra130----DM: 0.772, DBT: 0.851 (Y for readers with least experience), 1vDBT: 0.775 \[N\][^1] Table 2Recall rate and cancer detection rate - Comparison of DBT alone to DMAuthorYearVendorNRecall rateCancer detection rate \[/1000\]Aase et al2018GE14,274DBT: 3%, DM: 3.6% \[Y\]--Bian et al^a^2016Hologic631DM: 9.8%, DBT: 3.6% \[Y\]--Giess et al2017Hologic37,338DM: 10.3%, DBT: 10.7% \[N\]DM: 1.8, DBT: 3.8 \[Y\]Good et al2008Hologic30Malign. DM: 90.9%, DBT: 93.9%, non-malign: DM: 64.3%, DBT: 62.6% \[N\]--[^2]

### Sensitivity {#S0003-S2001-S3001}

Originally, DBT was assessed for its potential value as an additional technique following DM in patients referred with an abnormal screening mammogram or with clinical symptoms.[@CIT0015] In this prospective study, Teertstra et al assessed DBT *versus* DM separately, using Hologic systems (Lorad Selenia, an older version of Hologic DM and a prototype DBT) and 503 participants. No difference in sensitivity between the two systems was found. Later, Seo et al,[@CIT0016] in a study with Hologic Selenia Dimensions systems (most recent Hologic DM and DBT version) and 203 participants concluded that DBT has a higher sensitivity than DM.

A few studies on Hologic investigated the performance of DBT in comparison to DM, for different forms of breast cancer separately. Brandt et al (2013) carried out a study for non-calcifying lesions only and DBT was found to have similar sensitivity to DM. Bian et al[@CIT0017] found a statistically higher sensitivity for DBT than for DM for the detection of masses, specifically in dense breasts. On the other hand, other studies, which focused on calcifications only, found the sensitivity of DBT to be lower than DM, with the conclusion that DBT might miss a small number of this form of breast cancer.[@CIT0018],[@CIT0019]

With the above results, one could conclude that if either DM alone or DBT alone is used in breast screening, one form of breast cancer might be more likely to be missed. These concerns lead to some simulation studies using realistic breast tissue and real observers aiming to explain the above findings. It was concluded that DBT can outperform DM in masses detectability.[@CIT0020],[@CIT0021] However, the minimum detectable calcification diameter of DM and DBT were found to be 164±5 μm 210±5 μm respectively at standard dose.[@CIT0022] This difference in calcification diameter was explained by the lower sharpness and the lower modulation transfer function of DBT (Hologic Selenia Dimensions) compared to DM. DBT has a larger pixel pitch, due to pixel binning, as well as X-ray tube movement that introduces blurring.[@CIT0023] In addition, a slight further increase in geometric blurring might be introduced as the projection angle becomes wider.[@CIT0024]

However, conflicting conclusions were drawn in a recent study[@CIT0025] where it was shown that calcifications can be diagnosed using DM and DBT with similar sensitivity. Sensitivity for architectural distortions was also studied separately and DBT alone was found to outperform DM.[@CIT0026] The implementation of Hologic DBT alone in breast cancer screening remains controversial in research studies. However, conclusions from the above studies on Hologic do not necessarily apply to other manufacturers.

Studies using the Siemens DBT system include the one by Clauser et al[@CIT0027] in which microcalcifications only were investigated and an increased sensitivity with Siemens DBT was demonstrated compared to DM alone. It is worth noting though that the DM images were acquired with three different systems; Siemens, Sectra and GE, therefore DM and DBT compared are not of the same manufacturer in this case.

In a study using the Senographe Essential (GE Healthcare) system[@CIT0028] a significant outperformance was observed for 2vDBT in comparison to 2vDM in terms of sensitivity.

### Specificity {#S0003-S2001-S3002}

A small (non-significant) difference in specificity between DM and DBT were drawn in two studies for Hologic Selenia Dimensions systems.[@CIT0015],[@CIT0016] Regarding calcifications detection, two studies have shown that DBT outperforms DM in terms of specificity,[@CIT0018],[@CIT0025] while an only slightly better DBT performance was found by Spangler et al.[@CIT0019] Specificity was found to be similar between DM and DBT for architectural distortions[@CIT0026] and for non-calcifying lesions[@CIT0017],[@CIT0029] specifically for dense breasts, and for architectural distortions.[@CIT0026]

In a relatively small study (58 participants) GE DBT was found to outperform DM in terms of specificity.[@CIT0028]

### AUC {#S0003-S2001-S3003}

In terms of AUC, a non-statistically significant difference between the performances of DM and DBT for Hologic, was found in two studies,[@CIT0019],[@CIT0030] showing that the two imaging systems could equally distinguish between a cancerous and a non-cancerous group. Conflicting results were found by Seo et al 2016.[@CIT0016] Larger studies are required to support these studies' results and draw final conclusions on AUC, as their sample number is relatively small (30, 100 and 203 patients for[@CIT0016],[@CIT0019],[@CIT0030] respectively). Regarding architectural distortions, Dibbie et al[@CIT0026] have shown a higher AUC with DBT alone compared to DM.

For microcalcifications, a non-statistically significant increase in AUC was found for Siemens DBT systems compared to DM.[@CIT0027]

Wallis et al (2012) carried out a study using the Sectra photon counting DBT system.[@CIT0031] A significantly lower AUC was found for DM versus 2vDBT only when taking into account the results of the least experienced readers (five out of ten readers with less than 10 years of mammography experience).

### Recall rate {#S0003-S2001-S3004}

In two studies using Hologic[@CIT0030],[@CIT0032] a non-significant difference was found in the recall rate of the two imaging systems. On the other hand, a different study reported a significantly lower recall rate by DBT.[@CIT0017]

For GE, Aase et al[@CIT0033] reported a recall rate of 3.0% and 3.6% for DBT and DM respectively, a difference that was statistically significant.

### Cancer detection rate {#S0003-S2001-S3005}

For Hologic, a significantly higher cancer detection rate was found for DBT alone *versus* DM alone.[@CIT0032]

### Summary {#S0003-S2001-S3006}

In this section a comparison between DM alone and DBT alone was performed based on research studies. More studies were performed for some manufacturers than others and different conclusions can be drawn for different manufacturers. Studies using the most recent Hologic systems show that DBT alone might demonstrate better performance in terms of specificity and DM in terms of sensitivity, especially in the detection of calcifications, although not all studies reach this conclusion. AUC and recall rate seem to be at least similar for the two imaging systems, while a higher cancer detection rate was found for DBT. Studies on GE DBT have conflicting results, while Sectra results of one study show dependency on observer experience.

Digital breast tomosynthesis with digital mammography versus digital mammography {#S0003-S2002}
--------------------------------------------------------------------------------

It is often suggested by manufacturers that both DM and DBT should be used together (DM&DBT) in breast cancer screening. Some limitations include the increased reading time and image storage capacity. The main concern of introducing single or double-view DBT in screening together with DM is the additional dose to the patient or to the healthy woman who attends screening for early breast cancer diagnosis. There is the radiation protection requirement to keep the dose as low as reasonably practicable or in other words, to make sure that the diagnostic advantage of DBT outweighs the additional dose to the patient. Studies that investigated the diagnostic advantage of DM&DBT versus DM in terms of sensitivity, specificity, AUC, recall rate and cancer detection rate are summarised in [Tables 3](#T0003){ref-type="table"} and [4](#T0004){ref-type="table"} and are discussed below.Table 3Sensitivity, specificity and AUC - comparison of DM&DBT to DM alone, for all lesion typesAuthorYearVendorNSensitivitySpecificityAUCAlakhras et al2015Hologic50DM: 63.0%, DM&DBT: 70.4% \[Y\]DM: 65.2%, DM&DBT: 78.3% \[Y\]DM: 0.681, DM&DBT: 0.788 \[Y\]Alsheik et al2018Hologic, Siemens325,729DM: 87.9%, DM&DBT: 92.0% \[N\]DM: 89.5%, DM&DBT: 91.5% \[Y\]--Bansal et al2015Hologic103----DM: 0.721, DM&DBT: 0.901 \[N\]Bernardi et al2018Hologic9672DM: 46----100%, DM&DBT: 56----76%----Conant et al2016Hologic198,881DM: 90.6%, DBT: 90.9% \[N\]DM: 89.7%, DBT: 91.3% \[Y\]--Endo et al2017Fujifilm471----DM: 0.750, DM&DBT: 0.779--0.799 \[Y\]Gillbert et al2015Hologic7060DM: 87%, DM&DBT: 89% \[Y\]DM: 58%, DM&DBT: 69% \[Y\]DM: 0.84, DM&DBT: 0.89 \[Y\]Gur et al2011Hologic125----DM&DBT: 16% increaseHoussami et al2014Hologic7292DM: 54%, DM&DBT: 85%----Kim et al2017116DM: 58.3%, DBT&DM: 69.4%DM: 84.1%, DM&DBT: 85.9%--Mall et al2018Hologic144DM: 90%, DBT: 93%DM: 0.56, DM&DBT: 0.75DM: 0.872, DM&DBT: 0.927Mariscotti et al201683DM: 70%, DBT&DM: 85% \[Y\]--DM: 0.84, DBT&DM: 0.89Michell et al2012Hologic738DM: 40%, DM&DBT:58%DM: 51%, DM&DBT: 74.2%Significantly higher for DM&DBT for masses, slightly higher for DM&DBT for calcsOhashi et al2018GE628DM: 61%, DM&DBT: 83%DM: 99.1%, DM&DBT: 98.9%DBT&DM:0.9376, DM:0.9160 \[N\]Rafferty et al2013Hologic119211----16% increase with DBTDM (--)2% to 5% difference with DBT6.8--7.2% increase with the addition of DBTSeo et al2016Hologic203DM&DBT: 80%, DM: 73.2%, DBT:78.3% \[Y\]DM: 61%, DBT: 63%, DM&DBT: 64.3% \[N\]DM&DBT: 0.827, DM: 0.775, DBT:0.807 \[Y\]Singla et al2018Hologic100DM: 83.6%, DM&DBT: 100%DM: 38.78%, DM&DBT: 76.4%--Skaane et al2018Hologic84,178DM: 76.2%, DM&DBT: 80.8% \[N\]DM: 96.4%, DM&DBT: 97.5% \[Y\]--Thomassin--Naggara et al2015Hologic155DM: 72.9%, DM&DBT:89.3% \[Y\]DM: 50.5%, DM&DBT: 50.7% \[N\]--Tucker et al2017Hologic7060DM: 86%, DM&DBT:91% \[Y, for \<10 years of experience\]DM: 56%, DM&DBT: 68%--Yi et al^a^2018Hologic265DM: 59.1%, DM&DBT: 63.6% \[N\]DM: 75.8%, DM&DBT: 84.8% 75.8% \[N\]--[^3] Table 4Recall rate and cancer detection rate - comparison of DBT&DM to DMAuthorYearVendorNRecall rateCancer detection rate \[/1000\]Alsheik et al2018Hologic, Siemens325,729DBT&DM: 8.83%, DM: 10.98% \[Y\]DM: 3.8, DBT&DM: 4.8 \[Y\]Bahrs et al^b^2018Hologic8757.1% decrease with DBT--Bernardi et al2018Hologic9672DM&DBT: 1.6--4.6%, DM: 1.2--2.7%Increased CDR between 0--3.5Carbonaro et al2016Giotto280DM: 72----84% (92% double reading), DM&DBT: 42----57% (57% double reading)--Cohen et al2018Hologic103,070DM: 7.9%, DM&DBT: 6.1% \[Y\]DM: 4.0, DM&DBT: 4.8 \[N\]Conant et al2016Hologic198,881DM: 10.4%, DBT: 8.7% \[Y\]DM: 4.4, DM&DBT: 5.9 \[Y\]Destounis et al2014Hologic524DM: 11.45%, DM&DBT: 4.2% \[Y\]DM: 3.8, DM&DBT: 5.7 \[Y\]Durand et al2015Hologic17,955DM: 12.3%, DM&DBT: 7.8% \[Y\]--Friedewald et al2014Hologic454,850DM: 10.7%, DM&DBT: 9.1% \[Y\]DM: 4.2, DM&DBT: 5.4 \[Y\]Greenberg et al2014Hologic77,833DM: 16.2%, DBT&DM: 13.6% \[Y\]DM:4.9, DM&DBT: 6.3 \[Y\]Gur et al2009Hologic12530% decrease with DBT--Haas et al2013Hologic13,158DM: 12%, DM&DBT: 8.4% \[Y\]DM: 5.2, DM&DBT: 5.7 \[N\]Hakim et al2014Hologic36DM: 67%, DM&DBT: 42% \[Y\]--Houssami et al2014Hologic7292DM: 4.2%, DM&DBT: 5.3%^a^DM: 4.8, DM&DBT: 7.5 \[Y\]Lourenco et al2015GE, Hologic13,498DM: 9.3%, DBT&DM 6.4% \[Y\]DM: 5.4, DBT&DM: 4.6 \[Y\]Margolies et al2014Hologic996DBT decreased it by 8----25%DBT increased it by 20%McCarthy et al2015Hologic15,571DM: 10.4%, DM&DBT: 8.8% \[Y\]DM: 4.6, DM&DBT: 5.5 \[N\] (extra 0.9 per 1000 exams), For women under 50 yrs old: 5.7 vs 2.2 \[Y\]McDonald et al201623 958DM: 10.4%, DBT: 8.8% \[Y\]--Pan et al2018HologicNon--specifiedDM: 11.4--12.2%, DM&DBT: 9.0--10.1%DM: 6.3--8.1, DM&DBT: 8.5--11.4Pattacini et al2018GE19,560DM&DBT: 3.5%, DM: 3.5% \[N\]DM: 4.5, DM&DBT:8.6 \[Y\]Poplack et al2007Hologic99 (recalls)52% decrease with DBT--Powell et al2016Hologic12,781DM: 16%, DM&DBT: 14% \[Y\]DM: 5.2, DBT&DM: 7.8 \[N\]Rafferty et al2013Hologic1192Sig. reduction with DBT--Rose et al2013Hologic23,355DM: 8.7%, DM&DBT: 5.5% \[Y\]DM: 4.0, DM&DBT: 5.4 \[N\]Rose et al2014Hologic10,878DM: 8.88%, DM&DBT: 5.41% \[Y\]55% increase with DBTRose et al^c^2018Hologic59,921DM: 11.7%, DM&DBT: 10.9% \[Y\]DM: 1.9, DM&DBT: 2.7 \[Y\]Sharpe et al2016Hologic85,852DM: 7.51%, DBT: 6.10% \[Y\]--Singla et al2018Hologic100--DM: 7.3%, DM&DBT: 14.6% \[N\]Skaane et al2012Hologic129--4/84 women dismissed with DM, found suspicious with DBTSkaane et al^b^2013Hologic12,631--DM: 6.1, DM&DBT: 8.0 \[Y\]Skaane et al2018Hologic84,178DM: 6.7, DM&DBT: 3.6 \[Y\]DM: 6.3, DM&DBT: 9.3 \[Y\]Skaane et al^a^2013Hologic12,621--DM: 7.1, DBT&DM: 9.4 \[Y\]Sumkin et al2015Hologic1074DM: 38.4%, DM&DBT: 25.5% \[Y\]--Thomassin--Naggara et al2015Hologic155----Upadhyay et al2018Hologic880DM: 17.4%, DM&DBT: 11.4% \[Y\]--[^4]

### Sensitivity {#S0003-S2002-S3001}

A pilot observer study that compared DM to DM&DBT (DBT model: Genesis Tomosynthesis System, Hologic) was originally performed by with 30 participants.[@CIT0034] Results showed no improvement in observer performance with the addition of DBT. Later studies concluded that observer performance increases with the addition of DBT to DM when using more advanced Hologic models.[@CIT0013],[@CIT0016],[@CIT0035]--[@CIT0043] Specifically in the detection and characterization of invasive lobular cancers, DM&DBT significantly increases sensitivity compared to DM alone.[@CIT0044]

The TOMMY trial, carried out with 7060 patients in the United Kingdom, showed a marginal increase in sensitivity with borderline significance, with the addition of DBT to DM,[@CIT0045] while Tucker et al, using the same data concluded that sensitivity was increased for observers with less than 10 years of experience with the addition of DBT.[@CIT0046]

Recently, Skaane et al[@CIT0007] carried out a study, using the Oslo Trial data, in which 24,301 images acquired with DM&DBT were compared to 59,877 DM images of the same women acquired during prior rounds. Results showed that the addition of DBT gives a non-significant increase in sensitivity. In other large studies of 198,881 and 325,729 participants respectively, a non-significant difference in sensitivity was also found between DM and DM&DBT.[@CIT0047],[@CIT0048]

The majority of the above Hologic studies show an increase in sensitivity with the addition of DBT to DM, however, the three large studies in terms of participants' number, reported no statistical significance.

Not many studies were completed to date for other manufacturers. A retrospective study for GE was completed recently using 628 DM and DBT images from patients that had undergone mammography screening and had abnormal screening results or clinical symptoms. A statistically significant increase in sensitivity was found when adding DBT to DM.[@CIT0049]

### Specificity {#S0003-S2002-S3002}

Some studies show a significantly higher specificity with the addition of DBT to DM in screening.[@CIT0007],[@CIT0036],[@CIT0037],[@CIT0042],[@CIT0046],[@CIT0048],[@CIT0050],[@CIT0051] Other studies, however, concluded that there was a non-statistically significant increase.[@CIT0016],[@CIT0039],[@CIT0041] It should be noted that the three latter studies have in common a relatively small number of participants (100--200 women). Specifically, for "extremely dense breasts" Yi et al[@CIT0035] found a non-statistically significant difference in the specificity of the systems.

In the only GE study a statistically significant difference was found for specificity for DM&DBT over DM.[@CIT0049]

### AUC {#S0003-S2002-S3003}

In 2011, Gur et al reported a better performance, in terms of AUC, for DM&DBT *versus* DM alone.[@CIT0052] In a similar study[@CIT0036] AUC was found to be significantly better for Hologic DM&DBT than for DM alone, for masses, and only slightly better, for calcifications. Similar conclusions were later drawn in other studies for Hologic[@CIT0037],[@CIT0050] for all breast cancer mammographic appearances, and for invasive lobular cancers specifically.[@CIT0053] On the contrary to the above, a different study has shown a non-significant increase in AUC with the addition of DBT to DM.[@CIT0054]

In a GE study no significant difference was found for AUC for DM and DM&DBT.[@CIT0049]

In the only Fujifilm study identified for the purposes of this review, it was found that DM&DBT, in both modes (standard and high-resolution mode), outperforms DM alone in terms of AUC.[@CIT0055]

### Recall rate {#S0003-S2002-S3004}

[Table 4](#T0004){ref-type="table"} shows the results of the large number of studies on the comparison of the recall rate between DM and DM&DBT. For Hologic, there is a consistent agreement among all studies; they all show a decrease in recall rate when DBT is added to DM.[@CIT0007],[@CIT0034],[@CIT0038],[@CIT0039],[@CIT0042],[@CIT0047],[@CIT0048],[@CIT0056]--[@CIT0076] In all cases in which statistical significance information is provided, the decrease in recall rate is significant. Only one study was found to disagree,[@CIT0043] in which an increased false positive recall of 1.5--3.4% (median 2.75%) among radiologists for the DM&DBT compared to 1.2%-2.7% (median 2.25%) for DM was found.

Lourenco et al (2015) carried out a study with 12,577 DM examinations acquired on GE systems and 921 DM&DBT examinations acquired on Hologic systems; a study where the comparison of DM and DBT was not done on systems of the same manufacturer though.[@CIT0077]

With regards to studies on other manufacturers, one study on Giotto (Giotto, IMS, Italy) concluded in a significant decrease in recall rate with the addition of DBT to DM,[@CIT0078] while a study using the GE system showed no difference in the recall rate between the two imaging systems.[@CIT0079]

### Cancer detection rate {#S0003-S2002-S3005}

A number of studies in which Hologic systems are used to detect cancer agree that there is an increase in detection rate with the addition of DBT to DM; however, there is a conflict on whether this increase is significant.[@CIT0037],[@CIT0038],[@CIT0042],[@CIT0043],[@CIT0047],[@CIT0048],[@CIT0057]--[@CIT0061],[@CIT0063]--[@CIT0068],[@CIT0070],[@CIT0071],[@CIT0075]--[@CIT0077],[@CIT0080] Specifically, for ductal carcinoma in situ (an entity often presenting as microcalcifications), a significant difference was found in favor of DM&DBT versus DM alone.[@CIT0065]

In studies using the GE system a significantly higher cancer detection rate was found for DBT&DM compared to DM alone by two studies.[@CIT0077],[@CIT0079]

### Summary {#S0003-S2002-S3006}

There is a strong agreement in most of the above studies in that Hologic DM&DBT significantly outperforms DM alone in terms of specificity and recall rate. For GE, there are only a limited number of studies completed, which show that the addition of DBT to DM increases sensitivity and specificity, as well as cancer detection rate. In a single study with Fujifilm, DM&DBT was found to be advantageous over DM alone due to the higher AUC. Finally, Giotto's recall rate decreased in one study with the addition of DBT to DM.

It has not been adequately explored yet whether the benefit of the addition of DBT to screening outweighs the risk of additional radiation dose and whether DBT increases prevention of breast cancer deaths. There are though some new emerging studies on the assessment of interval cancers, whose data can predict the effect of DBT on the effectiveness of screening in preventing breast cancer deaths.[@CIT0007]

Single view digital breast tomosynthesis versus digital mammography {#S0003-S2003}
-------------------------------------------------------------------

As discussed in sections "Digital breast tomosynthesis alone versus digital mammography" and "Digital breast tomosynthesis with digital mammography versus digital mammography", for some manufacturers both DBT and DM might be necessary, mainly due to the possible superiority of DM in microcalcification detection and characterization, and the increased specificity and recall rate provided by DBT. Other more practical reasons of "not letting DM go" might include the comparisons with prior mammograms (that were also acquired with DM), the extra confidence it adds to diagnosis, as well as the "ease of using what is known". However, as discussed above, using both modalities, more than doubles the dose to the healthy woman who attends screening,[@CIT0006],[@CIT0014] as well as the reading time and the essential storage capacity. Thus, with the on-going evolution of DBT, several research groups had the idea to investigate the introduction of a 1vDBT into breast cancer screening, in addition to 1vDM or 2vDM ([Tables 5](#T0005){ref-type="table"} and [6](#T0006){ref-type="table"}) or alone, with the aim of keeping the dose levels lower than in the DM&DBT option. In this section these studies are discussed for different manufacturers and different single-view techniques.Table 5Sensitivity, specificity and AUC - comparison of 1vDBT with/without 1vDM or 2vDM and/or 1vSM, to 2vDMAuthorYearVendorNSensitivitySpecificityAUCChae et al2016GE319DM: 80.7%, 1vDBT: 88.7% \[Y\]DM: 93.2%, 1vDBT: 94.1% \[N\]DM: 0.93, 1vDBT: 0.96 \[Y\]Gennaro et al2010GE200DM: 74.3%, 1vDBT: 69.8% \[N\]DM: 84.8%, 1vDBT: 88.9% \[N\]DM: 0.84, 1vDBT: 0.85 \[N\]Gennaro et al2013GE463DM: 60.0%, 1vDM&1vDBT: 66.5% \[Y\]----Gennaro et al2013GE250DM: 72.8%, DM&1vDBT: 76.2% \[N\]DM: 83.0%, DM&1vDBT:84.9% \[N\]--Heywang--Kobrunner et al2018Siemens285DM: 90.9%, DM&1vDBT:96.4%, 1vDBT:96.4% \[N\]DM: 42.2%, DM&1vDBT: 54.3%, 1vDBT: 56.6% \[Y\]--Kang et al2016GE130DM: 73%, 1vDM&1vDBT: 69%, 1vSM&1vDBT: 83%, 1vDM&1vDBT&1vSM: 82%DM: 90%, 1vDM&1vDBT: 95%, 1vSM&1vDBT: 94%, 1vDM&1vDBT&1vSM: 95%DM: 0.881, 1vDM&1vSM: 0.848, 1vDM&1vDBT: 0.914, 1vDM&1vDBT&1vSM: 0.907Lang et al2016Siemens75001vDBT: 15% higher than DM--Rafferty et al2014Hologic1192DM: 62.7%, 1vDBT: 71.4%, DBT: 78.7% \[Y\]DM: 86.2%, 1vDBT: 86.0%, DBT: 84.5% \[N\]DM: 0.828, 1vDBT: 0.864, DBT: 0.895 \[Y\]Rodrigyez--Ruiz et al2018Siemens181DM: 76%, 1vDBT: 72%, 1vDM&1vDBT: 75%, DM&DBT: 76% \[N\]DM: 76%, 1vDBT: 74%, 1vDM&1vDBT: 72%, DBT&DM:73% \[N\]DM: 0.763, 1vDBT: 0.761, 1vDM&1vDBT: 0.772, DBT&DM:0.782 \[N\]Shin et al2015Hologic149DM: 82.4%, 1vDM&1vDBT:89.5% \[Y\]DM: 78.5%, 1vDM&1vDBT: 75.1% \[N\]DM: 0.869, 1vDM&1vDBT: 0.911 \[Y\]Svahn et al2010Siemens50----DM: 0.705, 1vDBT: 0.771, 1vDM&1vDBT: 0.818 \[N\]Svahn et al2012Siemens184DM: 78.9%, 1vDBT: 89.7%DM: 55.2%, 1vDBT: 54.4%DM: 0.706, DM&1vDBT: 0.809Thomassin--Naggara et al2017Hologic155DM: 72.9%, DM&1vDBT: 89.3%DM: 50.5%, DM&1vDBT: 50.7%DM: 0.685, DBT: 0.809Waldherr et al2013Hologic144DM:74.4%, 1vDBT: 88.4%, DM&DBT: 91.9%DM:76.8%, 1vDBT: 78.9%, DM&DBT: 75.4%--Whelehan et al2017Siemens238DM&1vDBT:90%, DM&supplementary views: 86% \[N\]DM&1vDBT:59%, DM&supplementary views: 64% \[Y\]DM&1vDBT:0.870, DM&SM: 0.857\[N\]Zackrison et al2018Siemens21,688DM: 60.4%, 1vDBT: 81.1%DM: 98.1%, 1vDBT: 97.2%--[^5] Table 6Recall rate and cancer detection rate - comparison of 1vDBT with/without 1vDM or 2vDM and/or 1vSM, to 2vDMAuthorYearVendorNRecall rateCancer detection rate \[/1000\]Rafferty et al2014Hologic1192DM: 44.2%, 1vDBT: 27.2%, DBT: 24.% \[Y\]--Lang et al2016Siemens7500DM: 2.6%, 1vDBT: 3.8%DM: 6.3, 1vDBT: 8.9Kang et al2016GE130DM: 23%, 1vDM&1vSM: 20%, 1vDM&1vDBT: 13%, 1vDM&1vDBT&1vSM: 12%--Zackrison et al2018Siemens21,688--DM: 6.5, 1vDBT: 8.7[^6]

### Sensitivity {#S0003-S2003-S3001}

Studies with Hologic systems showed a significant increase in sensitivity with the addition of one or two views of DBT to DM.[@CIT0039],[@CIT0081],[@CIT0082] For patients with abnormal mammograms, 1vDBT has higher sensitivity than DM, but a lower sensitivity than DM&DBT, for patients with fatty and dense breasts.[@CIT0083]

1vDBT (higher dose than normal 1vDBT dose) using the Siemens Mammomat Novation system and the Siemens Inspiration DBT system (Malmö, a population-based screening programme in Sweden) was compared to DM.[@CIT0084],[@CIT0085] An increase of 15% in sensitivity with 1vDBT compared to DM was reported.[@CIT0085] It is worth noting that out of the 67 lesions detected (in 7500 participants), only seven were microcalcifications, of which, one was missed by 1vDBT, but detected by DM. A potentially worse performance for microcalcifications by 1vDBT than by DM at the same dose, and the opposite for masses, was found in a simulation study for Mammomat Novation.[@CIT0086]

Using a Mammomat Siemens Inspiration it was shown that 1vDBT (MLO) does not have a statistically significant difference in sensitivity when compared with: (i) DM&DBT; (ii) DM; (iii) 1vDM&1vDBT.[@CIT0009] Similar results were found for soft tissue mammographic abnormalities separately.[@CIT0087] Other studies[@CIT0088],[@CIT0089] found that 1vDBT has higher sensitivity compared to DM.

Gennaro et al[@CIT0090] in a study with 200 women explored the clinical performance of 1vDBT (MLO) compared to DM by GE; a lower sensitivity was found for 1vDBT. On the contrary, in different retrospective studies 1vDBT was found to outperform DM.[@CIT0091] A study[@CIT0092] with 463 participants, investigated a different combination of views: 1vDM&1vDBT compared to DM alone; a significant increase was found in lesion detection with 1vDM&1vDBT. Finally, in a more recent study of different single-view and double-view implementations methods of GE, it was found that the combined use of CC-DM plus MLO-DBT with SM has a higher sensitivity than DM alone.[@CIT0093] The GE studies on 1vDBT alone or with DM, have shown that its sensitivity is non-inferior to DM.

### Specificity {#S0003-S2003-S3002}

Regarding Hologic, a non-significant increase in specificity with the addition of one or two views of DBT was shown.[@CIT0039],[@CIT0081]

1vDBT by Mammomat Novation Siemens was compared to DM;[@CIT0084] no difference in specificity was found by 1vDBT compared to DM. Rodriguez-Ruiz et al[@CIT0009] using 1vDBT (MLO) did not find a statistically significant difference in specificity when comparing it with: (i) DM&DBT; (ii) DM; (iii) 1vDM&1vDBT. Similarly, Zackrisson et al[@CIT0088] found that 1vDBT has a slightly lower specificity compared to DM, while a significant difference in specificity was found in favour of 1vDBT over supplementary mammography views, for soft tissue mammographic abnormalities.[@CIT0087]

A non-significant difference was found in the specificity of 1vDM&1vDBT[@CIT0090] or 1vDBT[@CIT0091],[@CIT0092] compared to DM alone for GE. However, specificity for benign lesions was found to be significantly higher with the combination of single views of the two techniques, compared to DM alone. As in the case of sensitivity, specificity was also found to increase with the combined use of CC-DM plus MLO-DBT with SM compared to DM.[@CIT0093]

### AUC {#S0003-S2003-S3003}

For Hologic, Rafferty et al,[@CIT0081] showed that the AUCs were 0.828, 0.864, and 0.895 for DM, DM&1vDBT, and DM&DBT, respectively. The addition of one view or two views of DBT to DM resulted in a significant difference in diagnostic accuracy compared with DM alone. Compared with DM, the AUC increased by 0.036 (*p*=0.009) with the addition of 1vDBT and increased by 0.068 (*p*\<0.001) with the addition of DBT; however, this difference did not meet their criterion of statistical significance (*p*\<0.0167). For the same manufacturer, Thomassin-Naggara et al[@CIT0039] and Shin et al[@CIT0082] showed that adding 1vDBT and 2vDBT respectively to DM improves the AUC, in comparison to DM alone.

1vDBT by Siemens Mammomat Novation was compared to DM and a higher diagnostic accuracy (ROC and JAFROC AUC) was found for 1vDBT compared to DM.[@CIT0084] On the contrary other studies showed a non-significant increase in AUC if 1vDBT or CC-DM with MLO-DBT are used instead of DM.[@CIT0009],[@CIT0094] In the Whelehan et al[@CIT0087] study, standard DM screening with additional supplementary views was found to have equivalent diagnostic accuracy in screen-detected soft tissue mammographic abnormalities and a non- significant difference in AUC of ROC analysis when compared to standard DM screening with 1vDBT.

There are conflicting conclusions on whether the difference in AUC by DM and 1vDBT by General Electric (GE) Senograph DS system is significant.[@CIT0091],[@CIT0092] In both of the above studies though, there was an increase in AUC when 1vDBT was used instead of DM, showing that 1vDBT is at least non-inferior to DM. In a comparison of DM to 1vDBT&DM,[@CIT0090] no significant difference in AUC was found.

### Recall rate {#S0003-S2003-S3004}

Rafferty et al[@CIT0081] used the Hologic system and showed that the addition of one-view or two-view DBT to DM resulted in significant reductions in recall rates, compared to DM alone. Additionally, DM with DBT also resulted in a significant reduction in recall rates compared with DM with DBT.

For Siemens Inspiration, results of the Malmö breast tomosynthesis screening trial[@CIT0085] demonstrated a significant increase in recall rate (46%) when using 1vDBT. However, the absolute increase in recall rate was actually very low (from 2.6% to 3.8%).

Finally, for GE, a significantly lower recall rate was found when using 1vDBT&1vDM compared to DM.[@CIT0093]

### Cancer detection rate {#S0003-S2003-S3005}

In the Malmö trial, using Siemens systems, the detection rate for 1vDBT was 8.9/1000 screens and for DM it was 6.3/1000 (significantly different); a 40% increase in cancer detection rate using DBT alone compared to DM. Zackirson et al also showed that there is an increased cancer detection rate using 1vDBT versus DM.[@CIT0088]

### Summary {#S0003-S2003-S3006}

The performance of a 1vDBT (and in some cases 1vSM too) in addition to single- or double-view DM is manufacturer dependent. Three studies that used Hologic systems show that the addition of a second view of DBT, to 2vDM, significantly improves the recall rate and increases but not necessarily significantly the sensitivity and AUC. The manufacturer does recommend using both views of DM and DBT (Hologic, Spring 2015). The GE studies using single-view combinations of DBT alone or with DM, have shown that its sensitivity is non-inferior to DM. A recent study also shows that it might be worth considering the use of 1vDBT&1vDM&1vSM, as it can increase sensitivity significantly. With regards to the use of 1vDBT of Siemens, provided the user has appropriate training, it has been concluded in several studies that 1vDBT is not inferior to DM.

Digital breast tomosynthesis with synthetic mammography versus digital mammography {#S0003-S2004}
----------------------------------------------------------------------------------

To overcome the disadvantage of additional dose when using DM&DBT, a synthetic 2D image (SM), which adds no extra dose, could be used with DBT instead. SM has completely replaced DM in some institutions; however, it might be fair to say that not all radiologists are fully convinced yet. There is ongoing work by several groups for its assessment and incorporation into the screening system worldwide. [Tables 7](#T0007){ref-type="table"} and [8](#T0008){ref-type="table"} and this section summarize these studies.Table 7Sensitivity, specificity and AUC - comparison of DBT&SM or SM to DM or of SM to DMAuthorYearVendorNSensitivitySpecificityAUCBerbardi et al2018Hologic9672SM: 56----76%, DBT&SM: 67----88%, DM: 46----100%----Choi et al^a^2016Hologic214SM:62.6----71%, DM: 60.7--71.0% \[N\]SM: 84.1--96.3%, DM: 72.9--94.4% \[N\]--Choi et al^b^2018Hologic198SM&DBT: 85.6%--95.6%, DM&DBT: 87.8--94.4%, SM: 84.4----90%, DM: 78.9--88.9%SM&DBT:100%, DM&DBT: 100%, SM: 100%, DM: 100%\[N\]Garayoa et al2018Hologic244DM: 79%, SM: 75% \[N\]DM: 81%, SM: 86% \[N\]DM: 0.87, SM:0.85 \[N\]Gillbert et al2015Hologic7060DM: 87%, DBT&SM: 88% \[N\]DM: 58%, DBT&SM: 71% \[Y\]DM: 0.84, DBT&SM: 0.87Gur et al2012Hologic114DM&DBT: 82.6%, DBT&SM: 77.2%DM&DBT comparable to DBT&SM--Mariscotti et al2017Hologic231SM: 92%, DM: 87% \[Y\]SM: 60%, DM: 62% \[N\]--Zuley et al2014Hologic123----DM&DBT: 0.92, DBT&SM: 0.94[^7] Table 8Recall rate and cancer detection rate - comparison of DBT&SM or SM to DM or of SM to DMAuthorYearVendorNRecall rateCancer detection rate \[/1000\]Ambinder et al2018Hologic22,621DBT&SM: 7.06%, DM&DBT: 7.63% \[Y\]DM&DBT: 5.25, DBT&SM: 5.57 \[N\]Aujero et al2017Hologic78,810DBT&SM: 4.3%, DM&DBT: 5.8% \[Y\], DM: 8.7% \[Y\]DM: 5.3, DM&DBT: 6.4, DBT&SM: 6.1 \[N\]Berbardi et al2018Hologic9672DM: 1.2--2.7%, SM: 1.6--4.6%, DBT&SM: 1.8--6.7%--Bernardi et al^a^2016Hologic9672DM: 3.4%, DBT&SM: 4.0%, DBT&SM: 4.5% \[Y\]DM: 6.3, DM&DBT: 8.5, DBT&SM: 8.8 \[Y\]Caumo et al2018Hologic34,071--DM: 9.3, DBT&SM: 5.41 \[Y\]Caumo et al^a^2018Hologic31,089DM: 4.2%, DM&DBT: 4.0%DBT&SM: 9.3, DM: 5.41 \[Y\]Freer et al2017Hologic31,979DBT&SM: 5.52%, DM: 7.83% \[Y\], DM&DBT: 6.39% \[N\]DM&DBT: 6.9, DBT&SM: 5.9, DM: 5.9Gur et al2012Hologic114DM&DBT: 29.8%, DBT&SM: 29.7% (for benign or no abnormality)Sixteen calcification clusters missed by all readers with DBT&SMHofvind et al2018Hologic98,927DBT&SM: 3.4%, DM: 3.3% \[N\]DBT&SM: 9.4, SM: 6.1 \[Y\]Martin et al2018Hologic16,067DM (double reading): 5%, DM&DBT&SM: 2.8% (single reading), DBT&SM: 2.9% \[N\]DM (double reading): 4.7%, DM&DBT: 5.4%, DM&DBT&SM: 5% (single reading) \[Y\]Skaane et al2014Hologic24,901--DM&DBT: 7.8, DBT&SM: 7.7Zuckerman et al2016Hologic15,571DBT&SM:7.1%, DM&DBT: 8.8% \[Y\]DBT&SM: 5.03, DM&DBT: 5.45 \[Y\]Zuley et al2014Hologic123DM: 90%, DM&DBT: 93%, DBT&SM: 95% \[N\]--[^8]

### Sensitivity {#S0003-S2004-S3001}

Lower sensitivity was observed with Hologic SM (known as C-view in the Hologic system) *versus* DM, both combined with DBT.[@CIT0095] Specifically, sixteen microcalcifications were missed or mis-interpreted using SM, while they were not missed with DM. However, this study was performed, before the Food and Drug Administration (FDA) approved Hologic SM to be used in combination with DBT in May 2013.

After the FDA approval, Choi et al directly compared DM (with double reading) to SM imaging and found comparable results in terms of sensitivity, specifically for T1-stage invasive breast cancers.[@CIT0096] The TOMMY trial, with 7060 participants, has shown an overall sensitivity of 87% for DM alone, and 88% for DBT&SM, ie not a significant difference between the two.[@CIT0045],[@CIT0051] Similar results were found specifically for microcalcifications.[@CIT0097],[@CIT0098] In two other studies a different there was an increased sensitivity by SM and DBT&SM compared to DM alone.[@CIT0043],[@CIT0044]

Most of the above studies for Hologic SM have shown a non-significant difference in sensitivity between SM or SM with DBT versus DM or DM with DBT, even though one of them concluded that SM outperforms DM.

### Specificity {#S0003-S2004-S3002}

A comparable specificity was observed with Hologic SM versus DM when either is combined with DBT, in the study by Gur et al before the FDA approval.[@CIT0095] Choi et al found comparable results, specifically for T1-stage invasive breast cancers.[@CIT0096] In the TOMMY trial a significant increase in specificity for DBT&SM versus DM was found. Specificity was shown to be lower for microcalcifications and higher for distortions.[@CIT0045] In more recent studies, a similar specificity between SM and DM, with or without DBT, was found.[@CIT0044],[@CIT0097],[@CIT0098] In conclusion, specificity was shown to be at least equivalent for Hologic DM and SM, and higher for DBT&SM when compared to DM alone.

### AUC {#S0003-S2004-S3003}

In terms of AUC, Zuley et al (2014) showed that Hologic SM alone or in combination with DBT is comparable to DM alone or in combination with DBT. Similarly, for microcalcifications, the comparison of DBT&SM versus DM&DBT versus SM versus DM concluded in a non-significant difference in AUC amongst the above methods.[@CIT0097] The direct comparison between DM and SM has shown a non-statistically significant difference in the AUC of the two systems.[@CIT0098]

### Recall rate {#S0003-S2004-S3004}

Early studies on Hologic SM have found similar recall rates for DM&DBT, DBT&SM,[@CIT0095],[@CIT0099] as well as DM and SM alone.[@CIT0099] Later studies, with a high number of participants (9672 and 15,571 respectively) have also shown an at least equivalent recall rate[@CIT0100]--[@CIT0103] in DBT&SM *versus* DM&DBT, if not higher.[@CIT0104] Significant differences in false positive recall rate when using DM alone versus DBT&SM, were found.[@CIT0100]

Bernardi et al 2018[@CIT0043] showed an increased false positive recall rate when using DBT&SM or SM alone, when compared to using DM alone. Sequential screen reading and the radiologists' inexperience with synthetic imaging are discussed in this study as partly explaining why an increment in false positive recall rate was documented.

Freer et al[@CIT0105] found a significantly lower recall rate with DBT&SM compared to DM alone. Other studies comparing Hologic DBT&SM versus DM&DBT also found a lower recall rate for the first modality compared to the second,[@CIT0106],[@CIT0107] claiming not just an equal, but an even better performance in terms of this metric for DBT&SM over DM&DBT.

### Cancer detection rate {#S0003-S2004-S3005}

Comparable cancer detection rates were found for Hologic DM&DBT and DBT&SM by Skaane et al[@CIT0108] in a prospective study with 24,901 participants (Oslo trial). In subgroup analyses according to tumor size and presence of calcifications, percentages of detected cancers and visibility scores were not significantly different. In a retrospective study with 15,571 participants, Zuckerman et al[@CIT0104] found a non-significant difference in the cancer detection rate between DM&DBT and DBT&SM. Similar conclusions were made in other studies.[@CIT0100],[@CIT0106],[@CIT0107]

Results have shown that cancer detection rate was significantly higher in patients screened with DBT&SM versus DM alone in the Verona Screening Programme too.[@CIT0109] Similar conclusions were drawn in other studies.[@CIT0102],[@CIT0103],[@CIT0105]

### Summary {#S0003-S2004-S3006}

All of the above studies are for Hologic SM, therefore they should not be generalized to any SM system and do not necessarily apply to other manufacturers. It can be concluded that, except for those studies undertaken before the FDA approval of SM, all studies support that the performance of SM together with DBT is at least equal, if not greater than that of DM and/or DM&DBT. Work is still being undertaken on the optimal utilization of SM.[@CIT0110] Training radiologists in SM, and specifically understanding the differences in the interpretation of SM images, in comparison and perhaps in parallel to DM images, might facilitate a wider acceptance of SM.

Discussion {#S0004}
==========

The aim of this review was to summarise clinical observer studies on the four common implementations with which DBT is considered for being introduced in screening: (1) DBT, (2) DM&DBT, (3) 1vDBT with or without 1vDM or 2vDM and (4) DBT&SM. An extensive literature review was undertaken on 89 original clinical observer studies (selected among 677 DBT studies for breast cancer screening), which evaluated one or more of the following metrics: sensitivity, specificity, AUC of ROC or JAFROC analysis, recall rate and/or cancer detection rate, for the assessment of one or more of the above implementations of DBT. Studies were discussed separately for the implementation of different DBT manufacturers to help diagnostic imaging professionals understand possible different optimal uses of different DBT systems.

This review does not directly compare implementations for different manufacturers, as studies are not always comparable, even when they assess the same metrics. Furthermore, this review does not present a head to head comparison of different manufacturers.

Hologic DBT was shown to be non-inferior to DM in several studies. However, some studies on Hologic raise a concern on the use of DBT alone in screening as DBT demonstrates better performance in terms of specificity and DM in terms of sensitivity, especially in the detection of calcifications. One could conclude that if only one of the two imaging systems is used in breast imaging, one radiological appearance of breast cancer might be more likely to be missed. When DBT together with DM is assessed versus DM alone, results showed that Hologic DBT with DM significantly outperforms DM alone in terms of specificity and recall rate, and in some studies in terms of sensitivity too. Three studies that used Hologic systems showed that the addition of the second view of DBT, to DM, significantly improves the recall rate and increases the sensitivity and AUC (not always with statistical significance). This is in agreement with the manufacturer's recommendations of using both views of DM and DBT.[@CIT0111] What has not been discussed extensively, to date whether the benefit outweighs the additional risk of cancer induction due to the additional dose. Except for those studies undertaken before the FDA approval of SM, all other studies on the use of C-view support that the performance of SM together with DBT, is at least equal, if not greater than that of DM and/or DM with DBT. As a technique, SM is still in its infancy so there remains work to be done to maximize its advantages and limit its drawbacks.[@CIT0110] What this review has not discussed are results on the new SM product by Hologic (Intelligence 2D), in which pixel size of the final DBT, and thus SM image, is smaller than that of the older-version C-view.

For Siemens, there seems to be the agreement of an increased DBT performance, if one-view high dose (compared to one-view normal dose) view is used, in comparison to DM, provided the user has been given appropriate training.[@CIT0009] For the same system, an increased recall rate and cancer detection rate were found for DBT.

The GE studies using single-view DBT versus DM have shown a non-significant difference in sensitivity and specificity, while there are conflicting results for AUC and recall rate. The combination of DBT with DM was shown to increase sensitivity, specificity and cancer detection rate. A recent study also shows that it might be worth considering the use of 1vDBT&1vDM&1vSM, as it can increase sensitivity significantly.

In the only Fujifilm study that met the inclusion criteria of this review, it was found that DM&DBT outperforms DM alone in terms of AUC of ROC analysis.[@CIT0055] With regards to studies on other manufactures, one study on Giotto (Giotto, IMS, Italy)[@CIT0078] showed a significant decrease in recall rate with the addition of DBT to DM. Wallis et al compared single-view Sectra photon counting DM&DBT system.[@CIT0031] A statistically significant difference was found in the AUC by DM versus DBT, only for five readers less than ten years of mammography experience. A non-significant difference was found when DM was compared to 1vDBT for ten readers that had mixed levels of experience.

Considerations for DBT implementation {#S0005}
=====================================

Based on the pool of studies used for the purposes of this review, it can be concluded that more studies have been completed for Hologic, compared to other manufacturers, especially for some of the implementation methods. For instance, for SM (section "Single view digital breast tomosynthesis versus digital mammography"), only studies involving Hologic were discussed. It is important to recognise that conclusions on implementations from different DBT manufactures do not necessarily apply to other manufacturers. Care should thus be taken when presenting or discussing DBT, as its optimum use might vary between different manufacturers. This is largely due to the different technical specifications of the different systems (section "This work").

For one imaging centre that is considering introducing DM and/or DBT it is important to use the right implementation based on the system that is available or will be bought. What will be bought or implemented, however, sometimes depends also on other practical, patient specific, staff training or financial factors. Therefore, care should be taken with the conclusions of original studies, as an adaptation might need to be made on the selection of the system in the particular centre.

There are other factors that can be incorporated into the methodology of the usage of an imaging implementation, and can affect the diagnostic performance of the system, that have not been addressed in this review. One of these factors is double image reading.[@CIT0112] As shown by Houssami et al single-reading of DBT (integrated DM&DBT or DBT&SM) detected more breast cancers and had a lower false positive recall rate, compared to double-reading DM alone. Similarly, the usage of prior mammograms might have an impact on the screening capabilities of a system. As shown by Kim et al,[@CIT0041] prior mammograms can affect the specificity of the imaging systems. In addition, as discussed above, patient specific background might affect the optimum usage of an imaging system and this has been recently assessed in a few studies.[@CIT0025],[@CIT0035] For example, the risk of cancer for a woman, which might be relevant to factors like history, age and breast density, might change the frequency and number of times a patient is screened and the implementation by which she is screened.

Finally, one interested in DBT implementation in breast cancer screening also owes to be aware of its possible drawbacks, including overdiagnosis and overtreatment. It has not been adequately explored yet whether DBT increases prevention of breast cancer deaths. There are on-going emerging studies on the assessment of interval cancers, whose data will predict the effect of DBT on the effectiveness of screening in preventing breast cancer deaths.[@CIT0007],[@CIT0113]

Conclusion {#S0006}
==========

Based on current knowledge, there appears to be benefit from the implementation of DBT in breast screening with or without DM and/or SM. DBT can perform at least equally to DM in most metrics and clinical scenarios; and in combination with DM and/or SM it can outperform DM, however this remains manufacturer- and metric- depended. More clinical observer studies were carried out using some DBT systems than others. For an implementation method of DBT by one manufacturer there might still be a shortage of studies, while for another implementation there might be conflicting results or even practical issues for implementation. In several cases, there is a strong agreement between studies, making the advantages and disadvantages of each system clear. The optimum implementation method, in terms of diagnostic benefit, together with the patient dose in mind, for one manufacturer does not necessarily apply to other manufacturers, due to the different technical specifications that different DBT systems have.
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[^1]: **Notes:** ^a^Calcifications; ^b^Non-calcified lesions; ^c^Masses, dense breast; ^d^Architectural distortions. \[Y\] = statistically significant, \[N\] = non-statistically significant, where available.

[^2]: **Note:** ^a^Masses, dense breast; \[Y\] = statistically significant, \[N\] = non-statistically significant, where available.

[^3]: **Notes:** ^a^"Extremely" dense breasts. \[Y\] = statistically significant, \[N\] = non-statistically significant, where available.

[^4]: **Notes:** ^a^false positive recall; ^b^BIRADS3; ^c^\<50 years old.

[^5]: **Notes:** \[Y\] = statistically significant, \[N\] = non-statistically significant, where available.

[^6]: **Notes:** \[Y\] = statistically significant, \[N\] = non-statistically significant, where available.

[^7]: **Notes:** ^a^T1-stage invasive; ^b^Microcalcifications. \[Y\] = statistically significant, \[N\] = non-statistically significant, where available.

[^8]: **Notes:** ^a^False positive recall. \[Y\] = statistically significant, \[N\] = non-statistically significant, where available.
